PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced receipt of the French 2019 Prix Galien Award for Most Innovative MedTech. The Companys lead product, HENSIFY (NBTXR3) brand name for the treatment of locally advanced Soft Tissue Sarcoma (STS), was recognized after receiving European market approval (CE marking, DM class III, on April 2, 2019) earlier this year. The Prix Galien Award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.
HENSIFY is a first-in-class radioenhancer consisting of an aqueous suspension of crystalline hafnium oxide nanoparticles. The product is administered only once, directly into the tumor, before a patients first radiotherapy session. After intratumoral injection, the nanoparticles penetrate the tumor cells and, when activated by ionizing radiation, deliver a larger energy deposit within the tumor where the nanoparticles are present, thereby increasing the tumor-killing effect of treatment without increasing damage to surrounding healthy tissues. HENSIFY has a universal, physical mode of action and is inert within the human body outside of the presence of ionizing radiation.
The product is approved in Europe for the treatment of Soft Tissue Sarcoma (STS). Positive results from the Companys phase III STS study were featured the August 2019 edition of The Lancet Oncology.
Moving forward, the Company is engaged in global clinical development of the product across fifteen (15) clinical trials in STS and other indications with a primary focus on global registration for the treatment of Head and Neck cancers. These trials include the expansion phase of a European phase I evaluating the safety and feasibility of NBTXR3 activated by radiation therapy(Study NBTXR3-102); an immuno-oncology (I/O) basket trial (Study NBTXR3-1100) which evaluates NBTXR3 in combination with anti-PD-1 in the United States (US); phase I trials evaluating NBTXR3 activated by radiation therapy for the treatment of liver and prostate cancer; a partnership with PharmaEngine in Asia evaluating NBTXR3 in combination with cisplatin; and a clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) including nine (9) trials across several indications.
About the PRIX GALIEN
Created in France in 1970, the Prix Galien is the most prestigious award in the field of pharmaceutical research and innovation. Referred to as the Nobel Prize of pharmaceutical research, it recognizes the efforts and achievements of pharmaceutical research and development.
About NBTXR3
NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide standards of radiation care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.
NBTXR3 is actively being evaluated in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I/II trial regarding local control. In the United States, the company has started the regulatory process in regard to the clinical authorization to the phase II/III in locally advanced head and neck cancers.
Nanobiotix is also running an Immuno-Oncology development program. The Company received approval FDA to launch a clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 antibodies in locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) and lung or liver metastasis (mets) with HNSCC not amenable to re-irradiation or non-small cell lung cancer (NSCLC) as the primary tumor.
The other ongoing NBTXR3 trials are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma. Furthermore, the company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.
About NANOBIOTIX: http://www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
See original here:
NANOBIOTIX Receives the 2019 Prix Galien Award for First-in-Class HENSIFY - Business Wire
- Advances in nanotechnology's fight against cancer [Last Updated On: December 27th, 2013] [Originally Added On: December 27th, 2013]
- Nanotechnology and Medicine - Nanomedicine and Disease ... [Last Updated On: December 27th, 2013] [Originally Added On: December 27th, 2013]
- Nanomedicine: Nanotechnology, Biology and Medicine - Official Site [Last Updated On: December 27th, 2013] [Originally Added On: December 27th, 2013]
- Nanomedicine Fact Sheet [Last Updated On: December 27th, 2013] [Originally Added On: December 27th, 2013]
- Nanomedicine, bionanotechnology | NanomedicineCenter.com [Last Updated On: December 27th, 2013] [Originally Added On: December 27th, 2013]
- Nanomedicine - Wikipedia, the free encyclopedia [Last Updated On: December 27th, 2013] [Originally Added On: December 27th, 2013]
- Nanomedicine for drug delivery - Srinivas Sridhar - Video [Last Updated On: December 28th, 2013] [Originally Added On: December 28th, 2013]
- IT-CRS 2013 workshop- Prof. Kevin Breackmans. Studying nanomedicine biobarriers - Video [Last Updated On: December 30th, 2013] [Originally Added On: December 30th, 2013]
- Nanotechnology in Medicine - UnderstandingNano [Last Updated On: January 3rd, 2014] [Originally Added On: January 3rd, 2014]
- Nanomedicine - Nanorobots in Medicine - UnderstandingNano [Last Updated On: January 8th, 2014] [Originally Added On: January 8th, 2014]
- Nanomedicine: Challenges and opportunities - Video [Last Updated On: January 13th, 2014] [Originally Added On: January 13th, 2014]
- Global Nanomedicine Market is Expected to Reach USD 177.60 Billion in 2019: Transparency Market Research [Last Updated On: January 16th, 2014] [Originally Added On: January 16th, 2014]
- NANOMEDICINE 1 - Video [Last Updated On: January 17th, 2014] [Originally Added On: January 17th, 2014]
- Researchers measure minuscule particles with 'tiny diving boards' [Last Updated On: January 20th, 2014] [Originally Added On: January 20th, 2014]
- High Unmet Needs in Therapeutics to Spur Growth in the Market for Nanotechnology in Drug Delivery, According to New ... [Last Updated On: January 21st, 2014] [Originally Added On: January 21st, 2014]
- Nanomedicine Market - Video [Last Updated On: January 22nd, 2014] [Originally Added On: January 22nd, 2014]
- Nanomedicine and human upper limit - Video [Last Updated On: January 23rd, 2014] [Originally Added On: January 23rd, 2014]
- Animated Nanomedicine movie - Video [Last Updated On: February 2nd, 2014] [Originally Added On: February 2nd, 2014]
- In Vitro Innovation: Testing Nanomedicine With Blood Cells On A Microchip [Last Updated On: February 4th, 2014] [Originally Added On: February 4th, 2014]
- Nanomedicine Market is Expected to Reach USD 177.60 Billion in 2019 [Last Updated On: February 7th, 2014] [Originally Added On: February 7th, 2014]
- NANOMEDICINE 4: AYDEN JACOB FROM UCSF - Video [Last Updated On: February 7th, 2014] [Originally Added On: February 7th, 2014]
- New Live-Cell Printing Technology Works Like Ancient Chinese Woodblocking [Last Updated On: February 10th, 2014] [Originally Added On: February 10th, 2014]
- NANOMEDICINE HANGOUT: ARSALAN SHABBIR MD - Video [Last Updated On: February 14th, 2014] [Originally Added On: February 14th, 2014]
- Using Mathematical Models to Understand Nanoscale Roughness Published by Dove Medical Press [Last Updated On: February 17th, 2014] [Originally Added On: February 17th, 2014]
- NTU and Northwestern University to set up $70 million nanomedicine research institute [Last Updated On: February 20th, 2014] [Originally Added On: February 20th, 2014]
- Interview with Medical Animator YURIY SVIDINENKO, about Nanotechnology Videos - Video [Last Updated On: February 21st, 2014] [Originally Added On: February 21st, 2014]
- TTU MSE nanomedicine lab NML 2013 f - Video [Last Updated On: February 21st, 2014] [Originally Added On: February 21st, 2014]
- Nanomedicine Vietsubtitles - Video [Last Updated On: February 24th, 2014] [Originally Added On: February 24th, 2014]
- Biochips for Better Cancer Therapy in NanoMedicine - Video [Last Updated On: February 27th, 2014] [Originally Added On: February 27th, 2014]
- 13 Nanomedicine Part 1 - Video [Last Updated On: February 28th, 2014] [Originally Added On: February 28th, 2014]
- 13 Nanomedicine part 2 - Video [Last Updated On: February 28th, 2014] [Originally Added On: February 28th, 2014]
- practicum nanomedicine pws Nicole en jordy - Video [Last Updated On: March 6th, 2014] [Originally Added On: March 6th, 2014]
- Nanomedicine, Detto tra Noi, 4 marzo 2014 - Video [Last Updated On: March 6th, 2014] [Originally Added On: March 6th, 2014]
- Brown Symposium XXXVI - Mauro Ferrari: "Nanomedicine and New Societal Horizons" - Video [Last Updated On: March 9th, 2014] [Originally Added On: March 9th, 2014]
- nanomedicine nanobiotix itele - Video [Last Updated On: March 9th, 2014] [Originally Added On: March 9th, 2014]
- NANOMEDICINE HANGOUT UNIVERSITY OF MIAMI ARSALAN SHABBIR MD - Video [Last Updated On: March 16th, 2014] [Originally Added On: March 16th, 2014]
- NANOMEDICINE HANGOUT1 - Video [Last Updated On: March 21st, 2014] [Originally Added On: March 21st, 2014]
- NANOMEDICINE HANGOUT - Video [Last Updated On: March 21st, 2014] [Originally Added On: March 21st, 2014]
- Ideas @Davos | Sonia Trigueros | Breakthroughs in Nanomedicine - Video [Last Updated On: March 22nd, 2014] [Originally Added On: March 22nd, 2014]
- Nanomedicine: towards development of patient-friendly drug-delivery systems - Video [Last Updated On: March 23rd, 2014] [Originally Added On: March 23rd, 2014]
- Nanomedicine Research [Last Updated On: March 26th, 2014] [Originally Added On: March 26th, 2014]
- Nanomedicinecenter.com - Nanomedicine, bionanotechnology ... [Last Updated On: August 18th, 2024] [Originally Added On: March 26th, 2014]
- Nanomedicine, Volume 1: Basic Capabilities [Last Updated On: August 18th, 2024] [Originally Added On: March 26th, 2014]
- Nanomedicine: towards development of patient-friendly drug-delivery systems - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 26th, 2014]
- Ideas @Davos | Sonia Trigueros | Breakthroughs in Nanomedicine - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 26th, 2014]
- NANOMEDICINE HANGOUT1 - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 26th, 2014]
- NANOMEDICINE HANGOUT - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 26th, 2014]
- Mining Genome Information for New Starting Points in Personalized Cancer Nanomedicine - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 27th, 2014]
- Mining Genome Information for New Starting Points in Personalized Cancer Nanomedicine - Video [Last Updated On: March 28th, 2014] [Originally Added On: March 28th, 2014]
- Cancer Stem Cells as Preferential Target for Personalized Cancer Nanomedicine - Video [Last Updated On: March 28th, 2014] [Originally Added On: March 28th, 2014]
- Nanomedicine Against Malaria: Use of Poly-based Nanovectors for the Drug Delivery to Plasmodium - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 29th, 2014]
- Panel - The Horizon of Nanomedicine and Targeted Drug Delivery - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 29th, 2014]
- Panel - The Regulation Environment in Nanomedicine -- The Step to the Last Phase of Translation - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 29th, 2014]
- Cancer Stem Cells as Preferential Target for Personalized Cancer Nanomedicine - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 29th, 2014]
- Nanomedicine Against Malaria: Use of Poly-based Nanovectors for the Drug Delivery to Plasmodium - Video [Last Updated On: March 29th, 2014] [Originally Added On: March 29th, 2014]
- Panel - The Horizon of Nanomedicine and Targeted Drug Delivery - Video [Last Updated On: March 29th, 2014] [Originally Added On: March 29th, 2014]
- Panel - The Regulation Environment in Nanomedicine -- The Step to the Last Phase of Translation - Video [Last Updated On: March 29th, 2014] [Originally Added On: March 29th, 2014]
- Looking and Listening to Light from Liposome Nanostructures for Cancer Theranostics - Video [Last Updated On: March 29th, 2014] [Originally Added On: March 29th, 2014]
- Looking and Listening to Light from Liposome Nanostructures for Cancer Theranostics - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 30th, 2014]
- NANOMEDICINE 3 Quantum Dot Technology for Multiplexing Applications# - Video [Last Updated On: August 18th, 2024] [Originally Added On: March 31st, 2014]
- Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of ... [Last Updated On: April 2nd, 2014] [Originally Added On: April 2nd, 2014]
- OMICS Groups Nanotechnology International Conference to Challenge the Old Frontiers [Last Updated On: August 18th, 2024] [Originally Added On: April 3rd, 2014]
- Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of ... [Last Updated On: August 18th, 2024] [Originally Added On: April 3rd, 2014]
- Breakthroughs in Nanomedicine-A World Economic Forum Discussion-Ideas @Davos-WIRED - Video [Last Updated On: April 4th, 2014] [Originally Added On: April 4th, 2014]
- How IBM Is Using Nanotechnology To Tackle MRSA And HIV [Last Updated On: August 18th, 2024] [Originally Added On: April 4th, 2014]
- How IBM Is Using Nanotechnology To Tackle MRSA And HIV [Last Updated On: April 5th, 2014] [Originally Added On: April 5th, 2014]
- In latest generation of tiny biosensors, size isn't everything [Last Updated On: April 14th, 2014] [Originally Added On: April 14th, 2014]
- In latest generation of tiny biosensors, size isn't everything [Last Updated On: August 18th, 2024] [Originally Added On: April 14th, 2014]
- Nanomedicine Research [Last Updated On: August 18th, 2024] [Originally Added On: April 14th, 2014]
- Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global ... [Last Updated On: April 17th, 2014] [Originally Added On: April 17th, 2014]
- Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global ... [Last Updated On: August 18th, 2024] [Originally Added On: April 18th, 2014]
- doctors-hospital-surgery-AFprelax-210414.jpg [Last Updated On: April 21st, 2014] [Originally Added On: April 21st, 2014]
- Nanomedicine - Video [Last Updated On: April 25th, 2014] [Originally Added On: April 25th, 2014]
- Nanomedicine - Video [Last Updated On: August 18th, 2024] [Originally Added On: April 25th, 2014]
- Nanomedicine Presentation - Video [Last Updated On: May 6th, 2014] [Originally Added On: May 6th, 2014]
- Nanomedicine Promo - Video [Last Updated On: May 6th, 2014] [Originally Added On: May 6th, 2014]
- Nanomedicine Presentation - Video [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2014]
- Nanomedicine Promo - Video [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2014]
- A skinful of nanoparticles starts to show [Last Updated On: May 16th, 2014] [Originally Added On: May 16th, 2014]
- nanomedicine edit1 - Video [Last Updated On: May 17th, 2014] [Originally Added On: May 17th, 2014]